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Early Clinical Manifestations and Eating Patterns in Patients with
Urea Cycle Disorders
Thatjana Gardeitchik, MD1,2, Maureen Humphrey, APD1,3, Judy Nation, APD1,3, and Avihu Boneh, MD, PhD1,4
Objectives To characterize dietary habits and eating patterns in patients with a urea cycle disorder (UCD), and to
identify dietary habits that may serve as clues to lead to earlier diagnosis of these disorders.
Study design This was a retrospective study of clinical and dietary data from hospital records of all patients with
UCD (n = 90) attending the Royal Children’s Hospital in Melbourne between 1972 and 2010.
Results Protein aversion, food refusal, frequent vomiting, poor appetite, and adverse reaction to high-protein–
containing foods were documented in the majority of patients with available detailed dietary protein intake data.
Fourteen of the 90 admissions for metabolic deterioration in which information regarding the precipitating factor(s)
were available were directly related to protein intake (5 higher and 9 lower than prescribed).
Conclusion Protein aversion is a common feature of UCD and may serve as a diagnostic clue in patients pre-
senting with food refusal, recurrent vomiting, behavioral problems, mental retardation, and “unexplained” epi-
sodes of altered consciousness. Dietary history should be included in the investigation of these symptoms,
which might lead to earlier diagnosis. Metabolic decompensation is more frequently related to low energy/protein
intake than to high protein intake in these patients. Special attention should be given to protein aversion, which
often leads to eating patterns that make it difficult for a patient to achieve the prescribed daily protein requirement.
(J Pediatr 2012;161:328-32).
U
rea cycle disorders (UCD) compromise a group of inherited metabolic disorders with an estimated overall preva-
lence of 1:30 000.1 Each of these disorders results from a deficiency of a particular enzyme along the hepatic am-
monia detoxification pathway. The 6 urea cycle enzymes are carbamoyl phosphate synthetase 1 (CPS1) and its
allosteric activator N-acetylglutamate synthetase, ornithine transcarbamylase (OTC), argininosuccinic acid synthetase
(ASS), argininosuccinic acid lyase (ASL), and arginase. The clinical manifestations of these disorders are variable, and
UCD phenotypes range from neonates dying from complications of hyperammonemia in the first week of life to apparently
asymptomatic adults.
Neonatal symptoms of UCD usually present after the first 24-48 hours of life in infants born at term after a normal pregnancy
and delivery. Common presenting symptoms are poor feeding, vomiting, lethargy, hypotonia, respiratory distress, irritability,
and seizures.Without treatment, patients may deteriorate rapidly, possibly to coma and death.2,3 Symptomatology in late-onset
forms of UCD is less marked, and patients may have less obvious features, which might lead to diagnostic delays.1,4-7 Reported
symptoms include episodes of altered consciousness, behavioral changes, irritability, abnormal motor function, seizures, cyclic
vomiting, loss of appetite, protein avoidance, poor growth, hypothermia, and developmental delay.1,4-7 The diagnosis may be-
come apparent during periods of metabolic stress (eg, infection, during pregnancy or the postpartum period).6,7 Dietary
changes (eg, high protein intake, persistent protein deficiency) also have been reported to precipitate presentation and deteri-
oration.5,6,8-10 Several patients have been reported in whom a detailed history obtained after presentation with severe neuro-
logic symptoms revealed severe, previously unrecognized protein aversion.9,11,12 The actual prevalence of this manifestation has
not been reported, however.
The objective of the present study was to identify dietary habits and eating patterns in patients with UCD before and after
diagnosis. We endeavored to find dietary clues that might lead to an earlier diagnosis of these disorders, which could poten-
tially prevent presentations with severe (ie, irreversible) neurologic symptoms.
We wished to identify dietary habits that might influence disease presentation
and frequency of episodes of metabolic deterioration, and also to identify prob-
lems that might require specific attention to the specialized care for these
patients.
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Methods
This study was part of a Metabolic Databank, which had been
approved by the Institutional Ethics Committee (HREC
30066A). Data for all patients attending the metabolic clinic
at the Royal Children’s Hospital, Melbourne, with a con-
firmed diagnosis of UCD between 1972 and 2010 were in-
cluded in this study. This clinic is a centralized service
managing all known patients with inborn errors of metabo-
lism in Victoria, Australia (current population of 5.5 mil-
lion). Diagnosis of UCD was considered confirmed if
a pathogenic mutation was identified, liver enzymology
showed reduced enzyme activity, a protein-loading test on
cascade screening was positive, or the patient presented
with an episode of hyperammonemia and amino acid and or-
otic acid analyses revealed characteristic abnormalities con-
sistent with a diagnosis of UCD. Patients were stratified
into a neonatal onset group, presenting during the first 28
days of life, and a postneonatal onset group. In addition, pa-
tients were divided according to mode of diagnosis: patients
who presented clinically, those detected by cascade screening,
and those detected through newborn screening.
Data were extracted from clinical patient charts, dietary re-
cords, and family genetic files, and were reviewed and coded
by one person. For each patient, along with data on the clin-
ical manifestations before or at the time of diagnosis, detailed
dietary information was collected, including protein aver-
sion, dietary changes before presentation, reported reactions
to protein-rich food, presence of food refusal, details on the
prescribed dietary regimen and general compliance, and self-
reported eating patterns before and after diagnosis.
Results
Data from all 90 patients with confirmed UCDwere included
in the analysis. Eight patients (5 males; 3 females) had CPS1
deficiency, 64 (24 males; 40 females) had OTC deficiency,
11 (4 males; 7 females) had ASS deficiency, and 7 (1 male; 6
females) had ASL deficiency. In 44 patients (including 4 iden-
tified on cascade screening), diagnosis wasmade after a symp-
tomatic presentation. Forty-one patients were identified by
cascade screening after a family member had been diagnosed
with UCD. Newborn screening identified 5 patients. In 1 pa-
tient, genetic screening for other medical reasons revealed
a deletion of the OTC gene. One female patient with OTC de-
ficiency was reportedly identified through routine screening
for phenylketonuria. In 2 female OTC-deficient patients, in-
formation on the mode of diagnosis was unavailable for re-
view. It should be noted that the retrospective nature of this
study dictated that the quality of data depended on the quality
of the records, and thus the extent of symptoms reported here
might be underestimated or, at times, overinterpreted.
Neonatal Presentation
Twenty-six patients presented with symptoms in the first 28
days of life, including 24 patients presenting in the first week.
This group comprised 14 patients with OTC deficiency
(all males), 4 with CPS1 deficiency, 6 with ASS deficiency,
and 2 with ASL deficiency. Four neonates in this group
(3 with OTC deficiency; 1 with CPS1 deficiency) presented
during careful observation instituted because of a positive
family history for UCD. The most common symptoms at
presentation were respiratory distress, poor feeding, lethargy,
and altered consciousness (Table I).
Postneonatal Presentation
Eighteen patients presented in the postneonatal period, with
only 2 diagnosed after their 18th birthday. (The exact date
of diagnosis was unavailable in 1 patient.) The median age
at diagnosis was 1.62 years (range, 0.11-43.14 years). The
most common symptoms at presentation were vomiting,
lethargy, and altered consciousness (Table I). A detailed
health history, including dietary history, was available in
17 patients and revealed unrecognized symptoms that could
have been suggestive of UCD before the actual presentation
that led to diagnosis. These included recurrent vomiting,
protein aversion, episodes of altered consciousness,
drowsiness, confusion, behavioral problems, and less
specific manifestations, including developmental delay,
lethargy when unwell, failure to thrive, cerebral palsy, and
hypotonia (Table II). None of these 17 patients reported
changes in diet immediately before clinical presentation.
The most common dietary characteristics before diagnosis
were protein aversion, food refusal, and adverse reactions to
high-protein foods. Adverse reactions were reported in 9
patients and included vomiting (7 patients) and irritability
after feeds in infancy (2 patients).
Cascade Screening
Forty-one patients were identified by cascade screening, and
subsequently diagnosed by a protein-loading test, mutation
analysis (including prenatal), or careful clinical and bio-
chemical observation of patients at risk during the newborn
Table I. Symptoms at presentation in patients with
neonatal onset and postneonatal onset
Neonatal onset (n = 26),
symptom (number of patients)
Postneonatal onset (n = 18),
symptom (number of patients)
Respiratory distress (15) Vomiting (7)
Poor feeding (13) Lethargy (7)
Lethargy (10) Altered consciousness (6)
Altered consciousness (10) Hypotonia (4)
Convulsions (8) Food refusal (4)
Vomiting (7) Irritability (4)
Irritability (7) Ataxia (3)
Hypotonia (4) Developmental delay (3)
Hypothermia (4) Poor growth (2)
Jitteriness (4) Convulsions (2)
Apnea (3) Confusion (2)
Tremors (2) Inappropriate behavior (1)
Hypertonia (1) Hypothermia (1)
Weight loss >10% (1) Incontinence (1)
Paresis (1)
Hypertonia (1)
Weight loss (1)
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period. Of the 9 patients in the latter group (5 with OTC de-
ficiency, 3 with CPS1 deficiency, 1 with ASS deficiency), 4 pa-
tients became symptomatic during the neonatal period (data
included in the neonatal presentation group) and 3 presented
with symptoms in the postneonatal period. Two of the 4 pa-
tients diagnosed by prenatal mutation analysis (all females
and OTC-deficient) became symptomatic. So far, the other
2 patients have not exhibited UCD-related symptoms. In
the postneonatal cascade screening group, 28 patients (25 fe-
males; 3 males) were diagnosed with OTC deficiency. The
median age at diagnosis was 25.85 years (range, 2-73 years)
in this group.
A detailed medical history was available in 25 of the 41 pa-
tients. Eight of these patients reported apparent UCD-related
symptoms that went unrecognized at the time, including re-
current vomiting and nausea, convulsions, episodic lethargy,
developmental delay, and jitteriness in infancy (Table II). A
dietary history was available in 21 of the 41 patients but was
incomplete in some, because of the retrospective data
retrieval. Eleven patients reported protein aversion, and 4
patients reported “feeling unwell” after eating protein-rich
foods.
Newborn Screening
Since 2002, when the extended newborn screening program
using tandem mass spectrometry was initiated in Victoria,
5 newborns have been identified with UCD (3 with ASS de-
ficiency, 2 with ASL deficiency), ranging in age from 3.5 to
7 years. Three patients were completely asymptomatic with-
out any form of treatment. One patient with ASL deficiency
was diagnosed with central nervous system periventricular
nodular heterotopia, most likely accounting for her develop-
mental delay and epilepsy. She experienced no episodes of
metabolic decompensation. One patient with ASL deficiency
(now 4 years old) presented with transient drowsiness and
poor feeding during a viral illness, but has had no other
symptomatology or recurrence and is on an unrestricted
normal diet.
Eating Patterns before and after Diagnosis
Sufficient information for calculating protein intake before
diagnosis was available in only 16 patients (6 in the cascade
screening group and 10 in the postneonatal presentation
group). These patients consumed 50%-60% of the median
protein content of a typical Australian child’s diet.13 Infor-
mation on dietary habits and eating patterns after diagnosis
was available in 67 patients and is summarized in Table III
according to specific diagnoses. Protein aversion was the
most striking reported feeding behavior, in particular
aversion to foods containing high protein density and
protein of high biological value, such as animal protein and
animal-derived proteins (eg, milk, eggs). Other reported
habits included increased feeding frequency, overeating of
low-protein foods, delay in self-feeding, food tantrums,
delayed introduction of solids, and high consumption of
low nutrient-dense foods. The number of patients was too
small to allow identification of differences in eating habits
in specific UCD diagnoses.
Hospital Admissions and Precipitating Factors
In 34 patients, the total number of admissions for metabolic
deterioration with hyperammonemia (neonatal deaths ex-
cluded) was 224 out of a total of 290 patient-years. Almost
all admissions of patients with UCD were at our center. A
precipitating factor was recorded in only 90 admissions,
with infection leading to 76 admissions, apparent inadequate
protein intake leading to 9 admissions, and apparent exces-
sive protein intake leading to 5 admissions. For all other ad-
missions, precipitating factors were not recorded or, more
typically, not known.
Discussion
This study aimed to identify early clinical manifestations and
eating patterns in patients with UCD, which could aid early
diagnosis of UCD. Although not all data of interest were
available for every patient, given the study’s retrospective na-
ture, considering the prevalence of UCD, our cohort of pa-
tients was sufficiently large to be informative regarding
clinical manifestations and dietary habits in patients with
these diseases. However, the number of patients with specific
diagnoses or genetic mutations was too small to allow us to
draw conclusions about differences in clinical parameters
and dietary habits among the various diseases.
Table II. Symptoms suggestive of UCD before the event
leading to diagnosis in patients with postneonatal onset
disease (n = 18) or before identification by cascade
screening (n = 25)
Postneonatal clinical onset (n = 18),
symptom (number of patients)
Cascade screening (n = 25),
symptom (number of patients)
Adverse reactions to high-protein
foods* (9)
Protein aversion (11)
Protein aversion (7) Recurrent vomiting (4)
Developmental delay (4) Nausea (1)
Lethargy when unwell (4) Convulsions (1)
Episodes of altered consciousness (2) Episodes of lethargy (2)
Drowsiness (2) Developmental delay (1)
Failure to thrive (2) Jitteriness in infancy (1)
Behavioral problems (1)
Episode(s) of confusion (1)
Cerebral palsy (1)
Hypotonia (1)
*Including vomiting (7) and irritability after feeds (2).
Table III. Eating behavior after UCD diagnosis
stratified by diagnosis
Diagnosis
(number of patients)
Protein
aversion
Poor
appetite
Food
refusal
Poor
variety
Frequent
vomiting
CPS1 deficiency (8*) 4 (4†) 3 (5) 5 (8) 2 (5) 4 (6)
OTC deficiency (47) 25 (39) 18 (29) 14 (34) 9 (28) 14 (37)
ASS deficiency (8) 2 (3) 2 (6) 7 (8) 4 (4) 5 (7)
ASL deficiency (4) 2 (4) 1 (4) 1 (3) 1 (4) 4 (6)
Total (67) 32 (50) 24 (44) 27 (53) 16 (41) 27 (56)
*Number of patients for whom information was available.
†Number of patients for whom information on the particular dietary habit was available.
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The variety of presenting symptoms in our population was
similar to that reported by others.1,3-6,14 The 3 most frequent
symptoms at presentation in the newborn period were respi-
ratory distress, poor feeding, and lethargy. In contrast, the
most common presenting manifestations in the postneonatal
onset group were episodes of vomiting, lethargy, and altered
consciousness (Table I).
Diagnostic delay is relatively common in UCD.1,4-6 The
number of patients diagnosed through cascade screening
who became symptomatic after a biochemical or genetic di-
agnosis underscores the importance of cascade screening in
the extended family when a new patient is diagnosed. Fur-
thermore, the finding of a history of unrecognized UCD
symptoms and protein aversion in almost half of the patients
in our cohort highlights the importance of meticulous
history-taking, including specific questions on dietary pro-
tein intake. This may lead to the suspicion of UCD in a child
referred for investigation of food refusal, repeated vomiting,
behavioral problems (eg, hyperactivity, agitation), mental re-
tardation, and unexplained altered consciousness. Food re-
fusal, poor appetite, and fussiness about eating are not
specific manifestations of UCD. Many children experience
a period of fussy eating behavior during the first few years
of life. Children with UCD present with protein aversion
and are especially fussy about meat, eggs, and dairy products
but do like fruit and vegetables, in contrast to most “normal”
fussy children, who tend to have more problems with vegeta-
bles. Patients and parents are not likely to volunteer this in-
formation themselves, because these dietary habits may seem
normal and have been observed since early childhood.
The mainstay of successful nutritional management of pa-
tients with UCD is maintaining nitrogen balance. Protein
must be sufficiently limited to minimize nitrogen overload
yet sufficiently abundant to maintain cellular function and
linear growth.7,15,16 Protein quality is just as important as
protein quantity in maintaining adequate metabolic control
and nutritional status, and must be considered when pre-
scribing a low-protein diet.
Complying with the prescribed protein and energy intake
may prove to be a major problem, and the literature is scanty
on eating behavior and compliance with dietary management
in patients with UCD and the influence on growth, general
well being, and frequency of metabolic deterioration. A study
of 1045metabolic deteriorations requiring hospitalization as-
cribed 15% of these deteriorations to noncompliance with
the prescribed diet; the authors did not distinguish between
higher or lower intake than prescribed, however.6 It has
been suggested that patients might eat more protein than rec-
ommended because of a reluctance to give up favorite foods,
poor acceptance by their families, or severe peer pressure.7,16
Indeed, high protein intake has been reported as a precipitat-
ing factor for metabolic decompensation in UCD.5,6,9,12,17
Those reports contrast with the findings of protein aversion
in our patients before diagnosis and failure to meet the pre-
scribed daily protein requirement after diagnosis. Indeed,
there have been reports of low protein intake in patients
with UCD due to pathological eating behavior and severe
protein self-restriction.16,18,19 In our cohort, 9 admissions
were due to ascertained low protein intake, which is probably
an underestimate. It is likely that 76 admissions were precip-
itated by an “intercurrent infection,” with reduced calorie
and protein intake in most of them. However, it is difficult
to distinguish between poor intake as the cause or the result
of decompensation, especially when reviewed retrospectively.
The most likely scenario would be a reduced protein and en-
ergy intake, leading to exacerbation of themetabolic derange-
ment. Further research should be carried out to quantify
these data and to analyze the effects on the number of meta-
bolic deteriorations, biochemical parameters, growth, and
general well being to eventually draw conclusions.
Finally, it should be noted that the eating patterns in chil-
dren with UCD can cause stress in families related to the
medical need to cope with a specific diet. In addition to the
actual calculation of dietary limits, attention should be paid
to the effects of the child’s diet and behavior on the family.
Counseling on the best way to handle possible problems
should be provided.
In conclusion, we recommend cascade screening of at-risk
patients after the diagnosis of a patient with UCD. A dietary
history, including questions about protein aversion, reaction
to protein-rich foods, and food refusal and fussiness, should
be included in the investigation of all patients presenting with
recurrent vomiting, behavioral issues, or unexplained altered
consciousness. This may lead to earlier diagnosis of UCD and
institution of treatment. n
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